Interstitial high dose rate brachytherapy in locally progressive or recurrent head and neck cancer.
Standard
Interstitial high dose rate brachytherapy in locally progressive or recurrent head and neck cancer. / Krüll, Andreas; Friedrich, R E; Schwarz, R; Thurmann, H; Schmelzle, R; Alberti, W.
In: ANTICANCER RES, Vol. 19, No. 4A, 4A, 1999, p. 2695-2697.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Interstitial high dose rate brachytherapy in locally progressive or recurrent head and neck cancer.
AU - Krüll, Andreas
AU - Friedrich, R E
AU - Schwarz, R
AU - Thurmann, H
AU - Schmelzle, R
AU - Alberti, W
PY - 1999
Y1 - 1999
N2 - In a retrospective study, 19 patients with progressive or recurrent head and neck cancer which had been treated with interstitial high dose rate brachytherapy were analysed. All of them had been previously treated with external radiation. Initial therapy further included surgery in 9 cases and chemotherapy in 3 patients. Staging according to the TNM system revealed advanced stage tumors in the majority of patients. Interstitial brachytherapy was carried out with the isotope Iridium-192. The applied total dose at the reference isodose varied between 10 and 30 Gy. Application was fractionated once a week. A complete tumor remission was achieved in 5 patients and partial remission in 10 patients. In 4 patients the tumor continued to grow despite brachytherapy. The mean follow-up in our collective was 21 months. The calculated local control rate was 34% at 24 months. The survival rate was 49% at 12 months and 35% at 24 months. Interstitial brachytherapy is recommended as a palliative treatment in preirradiated squamous cell carcinoma with local recurrence or progression.
AB - In a retrospective study, 19 patients with progressive or recurrent head and neck cancer which had been treated with interstitial high dose rate brachytherapy were analysed. All of them had been previously treated with external radiation. Initial therapy further included surgery in 9 cases and chemotherapy in 3 patients. Staging according to the TNM system revealed advanced stage tumors in the majority of patients. Interstitial brachytherapy was carried out with the isotope Iridium-192. The applied total dose at the reference isodose varied between 10 and 30 Gy. Application was fractionated once a week. A complete tumor remission was achieved in 5 patients and partial remission in 10 patients. In 4 patients the tumor continued to grow despite brachytherapy. The mean follow-up in our collective was 21 months. The calculated local control rate was 34% at 24 months. The survival rate was 49% at 12 months and 35% at 24 months. Interstitial brachytherapy is recommended as a palliative treatment in preirradiated squamous cell carcinoma with local recurrence or progression.
KW - Humans
KW - Survival Analysis
KW - Follow-Up Studies
KW - Disease-Free Survival
KW - Disease Progression
KW - Retrospective Studies
KW - Dose Fractionation
KW - Radiotherapy Dosage
KW - Neoplasm Staging
KW - Palliative Care
KW - Brachytherapy
KW - Carcinoma, Squamous Cell/mortality/pathology/radiotherapy
KW - Head and Neck Neoplasms/mortality/pathology/radiotherapy
KW - Neoplasm Recurrence, Local/mortality/pathology/radiotherapy
KW - Humans
KW - Survival Analysis
KW - Follow-Up Studies
KW - Disease-Free Survival
KW - Disease Progression
KW - Retrospective Studies
KW - Dose Fractionation
KW - Radiotherapy Dosage
KW - Neoplasm Staging
KW - Palliative Care
KW - Brachytherapy
KW - Carcinoma, Squamous Cell/mortality/pathology/radiotherapy
KW - Head and Neck Neoplasms/mortality/pathology/radiotherapy
KW - Neoplasm Recurrence, Local/mortality/pathology/radiotherapy
M3 - SCORING: Journal article
VL - 19
SP - 2695
EP - 2697
JO - ANTICANCER RES
JF - ANTICANCER RES
SN - 0250-7005
IS - 4A
M1 - 4A
ER -
